CelLBxHealth plc

London BTC Company has staked 36 mineral claims at its new Black Star gold-silver project in Nevada, with surface samples returning up to 16.23 grams per tonne gold. The project is the company's fourth in Nevada and sits just 16 miles from the 16.4 million ounce Hycroft Mine. In other company updates, CelLBxHealth reported its commercially weighted pipeline has grown to £3.5 million, with second-quarter revenue doubling to £0.4 million, and still expects at least £2.1 million in revenue for the full year. Anglo Asian Mining delivered record first-half copper production of 8,840 tonnes, driven by its Demirli mine ramp-up, with net cash climbing to £57.6 million after a $39.9 million cash build in the quarter. Galliford Try expects full-year profit at the top end of market forecasts, with cash up to £258.8 million and an order book of £4.3 billion, marking the sixth consecutive year of growth in revenue, profit and cash. Iofina produced a record 393 tonnes of iodine in the first half, beating its own upgraded guidance, and a new plant due online in September should push annual capacity significantly higher. NextEnergy Solar Fund has launched a formal sale process, inviting offers for the whole business, with shares rising 4% as the board moves to close a persistent discount to net asset value.

ACG Metals beat its full-year oxide production target in just six months, helped by a 64% jump in its realised gold price to $4,838 an ounce. First copper and zinc concentrate production is now expected in August. Rockfire Resources returned strong zinc and silver grades at its Molaoi project in Greece, with preliminary readings showing zinc values as high as 37.7%, and is fast-tracking feasibility studies and permit applications to reopen underground workings. Sunda Energy applied for a permit to explore an offshore area of New Zealand's Taranaki Basin covering around 645 square kilometres, triggering a three-month window for competing bids. CelLBxHealth remains on track for revenues of at least £2.1 million this year, up 50% on 2025, while searching for a new chief executive with no impact on trading expected. Poolbeg Pharma raised £3.5 million through a placing to fund two clinical trials and strengthen partnering discussions, extending its cash runway into the second quarter of 2028.

Solvonis Therapeutics says new data supports its lead alcohol use disorder programme ahead of a planned Phase 2b trial, with CEO Anthony Tennyson noting the results could streamline development and open access to a market of around 15 million US adults. Tertiary Minerals has started its biggest-ever drilling programme in Zambia, aiming to define a maiden resource while testing for extensions and a potentially deeper sulphide system. CelLBxHealth is reshaping its strategy around cancer diagnostics and new pharma partnerships, with collaborations with AstraZeneca and AdventHealth potentially expanding clinical use of its Parsortix platform. Coinsilium Group says Bitcoin remains just one part of its growth story, as it also targets opportunities in AI, prediction markets and blockchain infrastructure. Eco Buildings Group has begun building its AI-enabled manufacturing platform in Albania, designed to boost efficiency and support global expansion. Frontier IP Group says a €211 million funding boost for portfolio company 2D Photonics marks a major milestone, with CEO Neil Crabb also highlighting progress across its AI, energy and healthcare investments.

CelLBxHealth PLC reported full year 2025 results, highlighting strategic partnerships and cost reductions amid a revenue decline. Revenues fell from 2.9 million in 2024 to 1.4 million in 2025, while the operating loss reached 19.2 million, partly due to restructuring costs. The company has secured a master service agreement with AstraZeneca and is conducting clinical studies with Advent Health, and it is in discussions with about half of the top 10 pharma companies. Annualized cash operating costs were reduced by over 6.6 million, and operations were consolidated into a single site. Management noted that additional funding will be required by the second quarter of 2027 and emphasized a partnership-driven strategy to achieve revenue and profitability.

Eco Buildings Group has completed the second floor of its first apartment block in Albania, proving its prefab building system works at scale. The block of 18 apartments should bring in around €2.2 million in revenue upon completion, with five more blocks planned. Solvonis Therapeutics has cleared a key hurdle for its alcohol addiction treatment, showing it delivers the same drug levels as an approved depression medicine, clearing the path towards human trials within the next two years. Coinsilium Group has made a strategic investment in Predictive Labs, doubling down on prediction markets and AI, and also holds 50 million YELLOW tokens after a portfolio firm launched its trading platform. CelLBxHealth expects revenue of at least £2.1 million this year, up over 50%, after a year of deep restructuring, with new deals with AstraZeneca and AdventHealth backing up that growth target. NextEnergy Solar Fund says it can unlock up to £100 million of extra value through asset life extensions and a development pipeline, with generation coming in ahead of budget for the year to end March. Empire Metals has confirmed a huge high-grade titanium deposit in Western Australia, with some drill results topping 21% titanium dioxide, and an updated resource estimate due in the third quarter.

CelLBxHealth CEO Peter Collins described the first half of 2026 as an absolute whirlwind, with the company overhauling its business, product portfolio, and commercial strategy to improve circulating tumour cell recovery and viability. The company has secured a collaboration with AstraZeneca, which is interested in CTC-based analysis to support its oncology pipeline, and is working with AdventHealth on two large-scale cancer studies using the Parsortix platform to build clinical evidence for CTC-based patient monitoring. Collins noted that CTCs are required to address critical questions that ctDNA and tissue are unable to do, and he expects further partnering opportunities and progress toward clinical utility to support future growth. New board appointments bring added commercial, diagnostics, healthcare, and capital markets expertise to help drive execution, particularly in the US.